Prostate cancer market set to grow 50% by 2021: report

6 September 2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow from $4.4 billion to $6.6 billion by 2021, according to independent analyst Datamonitor Healthcare, which has revealed that the prostate cancer market is expected to grow by 50% over the next nine years.

The combined sales of prostate cancer drugs across the USA, Japan and the five major European Union markets (France, Germany, Italy, Spain and the UK) was worth $4.4 billion in 2012 and is expected to reach $6.6 billion by 2021, with a compound annual growth rate of 4.5%.

Growth will be due to uptake of new products, including Zytiga

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK